৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Products
Payment
Delivery
HPV vaccine is indicated for women aged 9–45 years.
Prevents diseases caused by HPV types 16 and 18:
Cervical cancer
Cervical intraepithelial neoplasia (CIN 1, 2, 3)
Adenocarcinoma in situ
Persistent HPV infections
Recombinant HPV type 16 L1 protein (40 µg)
Recombinant HPV type 18 L1 protein (20 µg)
Aluminum hydroxide adjuvant
Produced via recombinant DNA technology in E. coli
Standard schedule: 3 doses (0, 1, 6 months) intramuscularly in the deltoid.
Alternative schedule (ages 9–14): 2 doses (0 and 6 months).
Shake well before use; discard if abnormal appearance.
Not interchangeable with other HPV vaccines.
Hypersensitivity to active substances or excipients.
Postpone vaccination in case of acute serious febrile illness.
Local: Pain, redness, swelling.
Systemic: Fatigue, headache, myalgia, fever, nausea, dizziness.
Mostly mild to moderate.
Limited data; not recommended during pregnancy.
Use with caution in lactating women.
Does not replace cervical cancer screening.
Immunocompromised individuals may have reduced response.
Syncope (fainting) may occur; observe for 30 minutes post-vaccination.
Avoid mixing with other vaccines in the same syringe.
Human Papillomavirus Bivalent Vaccine is a preventive vaccine designed to protect against infection from two high-risk types of human papillomavirus (HPV): type 16 and 18. These strains are responsible for most cases of cervical cancer and several other HPV-related cancers.
This vaccine helps prevent cervical cancer, precancerous cervical lesions, and other HPV-related cancers (such as vaginal and vulvar cancers). It is most effective when given before exposure to HPV, typically in adolescents and young adults.





